Welch & Forbes’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$155M Buy
168,235
+417
+0.2% +$423K 2% 12
2025
Q4
$180M Sell
167,818
-378
-0.2% -$361K 2.19% 9
2025
Q3
$128M Buy
168,196
+18,751
+13% +$14M 1.55% 13
2025
Q2
$116M Buy
149,445
+910
+0.6% +$707K 1.45% 18
2025
Q1
$123M Buy
148,535
+1,555
+1% +$1.29M 1.61% 15
2024
Q4
$113M Buy
146,980
+12,088
+9% +$10M 1.46% 17
2024
Q3
$120M Sell
134,892
-2,553
-2% -$2.3M 1.52% 17
2024
Q2
$128M Buy
137,445
+1,626
+1% +$1.3M 1.71% 15
2024
Q1
$106M Buy
135,819
+2,726
+2% +$1.94M 1.45% 20
2023
Q4
$77.6M Buy
133,093
+3,340
+3% +$1.95M 1.17% 25
2023
Q3
$69.7M Buy
129,753
+7,896
+6% +$4.07M 1.15% 27
2023
Q2
$57.1M Sell
121,857
-971
-0.8% -$407K 0.9% 34
2023
Q1
$42.2M Buy
122,828
+1,584
+1% +$534K 0.71% 42
2022
Q4
$44.4M Sell
121,244
-350
-0.3% -$124K 0.8% 39
2022
Q3
$39.3M Sell
121,594
-2,596
-2% -$823K 0.77% 40
2022
Q2
$40.3M Sell
124,190
-4,250
-3% -$1.28M 0.74% 43
2022
Q1
$36.8M Sell
128,440
-1,085
-0.8% -$279K 0.58% 50
2021
Q4
$35.8M Buy
129,525
+225
+0.2% +$57K 0.54% 51
2021
Q3
$29.9M Buy
129,300
+100
+0.1% +$24.7K 0.5% 55
2021
Q2
$29.7M Buy
129,200
+1,515
+1% +$304K 0.5% 55
2021
Q1
$23.9M Sell
127,685
-834
-0.6% -$163K 0.44% 59
2020
Q4
$21.7M Buy
128,519
+135
+0.1% +$20.2K 0.42% 64
2020
Q3
$19M Buy
128,384
+2,930
+2% +$453K 0.41% 66
2020
Q2
$20.6M Sell
125,454
-3,000
-2% -$460K 0.48% 58
2020
Q1
$17.8M Sell
128,454
-1,650
-1% -$227K 0.5% 60
2019
Q4
$17.1M Sell
130,104
-665
-0.5% -$77.1K 0.38% 78
2019
Q3
$14.6M Sell
130,769
-2,775
-2% -$309K 0.35% 79
2019
Q2
$14.8M Sell
133,544
-978
-0.7% -$115K 0.36% 77
2019
Q1
$17.5M Buy
134,522
+29
+0% +$3.53K 0.44% 63
2018
Q4
$15.6M Sell
134,493
-2,540
-2% -$284K 0.44% 68
2018
Q3
$14.7M Sell
137,033
-4,549
-3% -$455K 0.35% 82
2018
Q2
$12.1M Sell
141,582
-2,705
-2% -$222K 0.31% 89
2018
Q1
$11.2M Sell
144,287
-1,681
-1% -$135K 0.29% 93
2017
Q4
$12.3M Buy
145,968
+1,123
+0.8% +$95.6K 0.33% 83
2017
Q3
$12.4M Sell
144,845
-275
-0.2% -$22.6K 0.33% 90
2017
Q2
$11.9M Buy
145,120
+460
+0.3% +$37.5K 0.33% 86
2017
Q1
$12.2M Sell
144,660
-660
-0.5% -$52.9K 0.35% 84
2016
Q4
$10.7M Sell
145,320
-353
-0.2% -$26.3K 0.32% 87
2016
Q3
$11.7M Sell
145,673
-1,866
-1% -$149K 0.4% 74
2016
Q2
$11.6M Buy
147,539
+446
+0.3% +$33.6K 0.35% 87
2016
Q1
$10.6M Sell
147,093
-3,376
-2% -$255K 0.33% 89
2015
Q4
$12.7M Sell
150,469
-910
-0.6% -$75.5K 0.41% 79
2015
Q3
$12.7M Sell
151,379
-5,765
-4% -$487K 0.42% 75
2015
Q2
$13.1M Sell
157,144
-4,254
-3% -$324K 0.41% 74
2015
Q1
$11.7M Sell
161,398
-2,413
-1% -$172K 0.35% 80
2014
Q4
$11.3M Buy
163,811
+345
+0.2% +$23.3K 0.33% 86
2014
Q3
$10.6M Sell
163,466
-790
-0.5% -$50K 0.32% 82
2014
Q2
$10.2M Buy
164,256
+419
+0.3% +$25K 0.32% 83
2014
Q1
$9.64M Sell
163,837
-798
-0.5% -$44.5K 0.31% 90
2013
Q4
$8.4M Buy
164,635
+4,972
+3% +$249K 0.27% 94
2013
Q3
$8.04M Sell
159,663
-966
-0.6% -$50.6K 0.27% 95
2013
Q2
$7.89M Buy
+160,629
New +$8.74M 0.28% 92

Other funds holding LLY

Welch & Forbes's LLY Position: Q1 2026 in Review

Welch & Forbes increased its Eli Lilly (LLY) stake by 0.25% in Q1 2026, buying an estimated $423K and bringing the position to 168,235 shares worth $155M. The position accounts for 2% of the portfolio, ranked #12.

Welch & Forbes first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $180M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Welch & Forbes held 168,235 shares of Eli Lilly worth $155M as of Q1 2026.
  • Welch & Forbes bought 417 Eli Lilly shares in Q1 2026, an estimated $423K.
  • Eli Lilly made up 2% of Welch & Forbes's portfolio in Q1 2026, its #12 holding.
  • Welch & Forbes first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Welch & Forbes's Eli Lilly position peaked at $180M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Welch & Forbes's 13F filing for Q1 2026, filed 1 May 2026.